BRCA1 and neoplasm: In circumstances when tumour samples are not available or the quality of the tumour material is inadequate for NGS, and a re-biopsy is challenging, then germline testing could be performed, with most laboratories currently undertaking panel testing of key germline HRR alterations including BRCA1/2.